OBJECTIVE: HIV-1 can use various G protein-coupled receptors (GPCRs) in addition to CCR5 and CXCR4 as coreceptors; however, this type of HIV-1 infection has hardly been detected in vivo. The objective of this study was to elucidate the spectrum of GPCR usage by HIV-1 populations in vivo. DESIGN: CD4-expressing glioma cell line, NP-2/CD4, becomes highly susceptible to HIV-1 when the cells express GPCRs with coreceptor activities. This cell system was advantageous for detecting the inefficient use of GPCRs by HIV-1. METHODS: We developed NP-2/CD4/GPCR cells that express each of 23 GPCRs: 21 chemokine receptors (CCR1, CCR2b, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9B, CCR10, CCR11, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CX3CR1, XCR1, D6, and DARC) and two other GPCRs (a formylpeptide receptor, FPRL1, and an orphan GPCR, GPR1). NP-2/CD4/GPCR cells were directly cocultured with HIV-1-positive peripheral blood lymphocytes and HIV-1 infection was detected. RESULTS: Primary HIV-1 isolates were obtained from NP-2/CD4/GPCR cells expressing CCR5, CXCR4, FPRL1, or GPR1 cocultured with 11 of 17 peripheral blood lymphocytes. Surprisingly, these isolates showed extremely expanded GPCR usage, such as CCR1, CCR3, CCR5, CCR8, CXCR4, D6, FPRL1, and GPR1 as coreceptors. We found that CCR9B, CCR10, and XCR1 also work as novel HIV-1 coreceptors. CONCLUSION: FPRL1 and GPR1 have the potential to work as significant HIV-1 coreceptors in vivo next to CCR5 and CXCR4. HIV-1 populations that can use various GPCRs as coreceptors are already circulating in vivo, even in the early stage of HIV-1 infection.
OBJECTIVE:HIV-1 can use various G protein-coupled receptors (GPCRs) in addition to CCR5 and CXCR4 as coreceptors; however, this type of HIV-1 infection has hardly been detected in vivo. The objective of this study was to elucidate the spectrum of GPCR usage by HIV-1 populations in vivo. DESIGN:CD4-expressing glioma cell line, NP-2/CD4, becomes highly susceptible to HIV-1 when the cells express GPCRs with coreceptor activities. This cell system was advantageous for detecting the inefficient use of GPCRs by HIV-1. METHODS: We developed NP-2/CD4/GPCR cells that express each of 23 GPCRs: 21 chemokine receptors (CCR1, CCR2b, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9B, CCR10, CCR11, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CX3CR1, XCR1, D6, and DARC) and two other GPCRs (a formylpeptide receptor, FPRL1, and an orphan GPCR, GPR1). NP-2/CD4/GPCR cells were directly cocultured with HIV-1-positive peripheral blood lymphocytes and HIV-1 infection was detected. RESULTS: Primary HIV-1 isolates were obtained from NP-2/CD4/GPCR cells expressing CCR5, CXCR4, FPRL1, or GPR1 cocultured with 11 of 17 peripheral blood lymphocytes. Surprisingly, these isolates showed extremely expanded GPCR usage, such as CCR1, CCR3, CCR5, CCR8, CXCR4, D6, FPRL1, and GPR1 as coreceptors. We found that CCR9B, CCR10, and XCR1 also work as novel HIV-1 coreceptors. CONCLUSION:FPRL1 and GPR1 have the potential to work as significant HIV-1 coreceptors in vivo next to CCR5 and CXCR4. HIV-1 populations that can use various GPCRs as coreceptors are already circulating in vivo, even in the early stage of HIV-1 infection.
Authors: Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao Journal: J Virol Date: 2011-08-10 Impact factor: 5.103
Authors: V R Joag; L R McKinnon; J Liu; S T Kidane; M H Yudin; B Nyanga; S Kimwaki; K E Besel; J O Obila; S Huibner; J O Oyugi; J Arthos; O Anzala; J Kimani; M A Ostrowski; R Kaul Journal: Mucosal Immunol Date: 2015-04-15 Impact factor: 7.313
Authors: Michael Roche; Martin R Jakobsen; Jasminka Sterjovski; Anne Ellett; Filippo Posta; Benhur Lee; Becky Jubb; Mike Westby; Sharon R Lewin; Paul A Ramsland; Melissa J Churchill; Paul R Gorry Journal: J Virol Date: 2011-02-23 Impact factor: 5.103
Authors: Ana M Sanchez; C Todd DeMarco; Bhavna Hora; Sarah Keinonen; Yue Chen; Christie Brinkley; Mars Stone; Leslie Tobler; Sheila Keating; Marco Schito; Michael P Busch; Feng Gao; Thomas N Denny Journal: J Immunol Methods Date: 2014-01-19 Impact factor: 2.303
Authors: Timothy J Henrich; Emily Hanhauser; Zixin Hu; Hans-Jürgen Stellbrink; Christian Noah; Jeffrey N Martin; Steven G Deeks; Daniel R Kuritzkes; Florencia Pereyra Journal: AIDS Date: 2015-05-15 Impact factor: 4.177
Authors: Yin Xu; Chris Weatherall; Michelle Bailey; Sheilajen Alcantara; Robert De Rose; Jerome Estaquier; Kim Wilson; Kazuo Suzuki; Jacques Corbeil; David A Cooper; Stephen J Kent; Anthony D Kelleher; John Zaunders Journal: J Virol Date: 2013-01-16 Impact factor: 5.103
Authors: Hamid Salimi; Michael Roche; Nicholas Webb; Lachlan R Gray; Kelechi Chikere; Jasminka Sterjovski; Anne Ellett; Steve L Wesselingh; Paul A Ramsland; Benhur Lee; Melissa J Churchill; Paul R Gorry Journal: J Leukoc Biol Date: 2012-10-17 Impact factor: 4.962